UBS Group
AMLX icon

UBS Group’s Amylyx Pharmaceuticals AMLX Stock Holding History

UBS Group’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-27,900
Closed -$602K – 9421
2023
Q2 		$602K Hold
27,900
– – ﹤0.01% 4669
2023
Q1 		$819K Hold
27,900
– – ﹤0.01% 4279
2022
Q4 		$1.03M Buy
+27,900
New +$990K ﹤0.01% 4043

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

UBS Group's AMLX Position: Q1 2026 in Review

UBS Group reduced its Amylyx Pharmaceuticals (AMLX) stake by 40% in Q1 2026, selling an estimated $3.08M and leaving 324,319 shares worth $4.51M. The position accounts for ﹤0.01% of the portfolio, ranked #4176.

UBS Group first reported a position in AMLX in Q1 2022 and has held it in 17 quarters since. The position peaked at $19.1M in Q3 2025. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

  • UBS Group held 324,319 shares of Amylyx Pharmaceuticals worth $4.51M as of Q1 2026.
  • UBS Group sold 219,004 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $3.08M.
  • Amylyx Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #4176 holding.
  • UBS Group first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 17 quarters since.
  • UBS Group's Amylyx Pharmaceuticals position peaked at $19.1M in Q3 2025.
  • 171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.